MGT SVCS/CONTRACT & PROCUREMENT SUP

为了解决缺乏有效治疗神经系统疾病的问题，美国国立卫生研究院建立了蓝图神经治疗网络（http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm）。该项目旨在通过临床I期成功开发药物，并促进行业伙伴关系的全面开发。这一重大挑战的长期目标是，针对目前治疗或治疗不善的神经系统疾病，生产出至少一种新颖有效的药物。美国国立卫生研究院蓝图神经治疗网络正在建立一个具有丰富行业经验的合同服务提供商和顾问的“虚拟制药”网络，以使美国国立卫生研究院神经科学研究界的药物开发成为可能。该网络为神经科学研究人员提供了全方位的行业式药物开发服务和专业知识，包括药物化学、ind研究和1期临床试验基础设施。神经治疗项目的药理学和毒理学（PTNP）合同支持所有临床前药理学和毒理学测试，为先导优化和临床候选药物的选择提供信息，并为FDA的研究性新药（IND）申请提供全面的研究，以允许对新化学实体进行临床评估。

To address the paucity of effective treatments for disorders of the nervous system, the NIH has established the Blueprint Neurotherapeutics Network (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). This program intends to develop drugs successfully through clinical Phase I and facilitate industry partnerships for their full development. The long-term goal of this grand challenge is to produce at least one novel and effective medication for a disorder of the nervous system that is currently poorly treated or untreated. The NIH Blueprint Neurotherapeutics Network is establishing a ¿virtual pharma¿ network of contract service providers and consultants with extensive industry experience to enable drug development in the NIH neuroscience research community. The Network offers neuroscience researchers access to a full range of industry-style drug development services and expertise, including medicinal chemistry, IND-enabling studies, and Phase 1 clinical trial infrastructure. The Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) contracts support all preclinical pharmacology and toxicology testing needed to inform lead optimization and the selection of a clinical candidate, and comprehensive studies needed for an Investigational New Drug (IND) application for the FDA to allow for clinical evaluation of New Chemical Entities.